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Summary Eighty-one patients with advanced breast cancer completed the Hospital Anxiety and Depression
Scale (HADS) and Rotterdam Symptom Checklist (RSCL) to determine how well these questionnaires
identified patients suffering from an anxiety state or depressive illness, compared with an independent
interview by a psychiatrist who used the Clinical Interview Schedule. A threshold score was defined for each
questionnaire which gave the optimal sensitivity and specificity. Seventy-five per cent of patients were correctly
identified as suffering from an affective disorder by both the Rotterdam Symptom Checklist and by the
Hospital Anxiety and Depression Scale. Twenty-one per cent of 'normal' patients were misclassified by the
Rotterdam Checklist and 26% by the Hospital Anxiety and Depression Scale. When the HADs anxiety and
depression subscales were analysed separately, the performance of the anxiety items was superior to that of the
depression items. Both questionnaires were found to have good predictive value and could be used in patients
with advanced cancer to help screen out those with an affective disorder.
Clinicians treating women with advanced breast cancer have
become increasingly concerned about their quality of life
(Baum et al., 1980; Bell et al., 1985; Brinkely, 1985; Coates et
al., 1987; Gough et al., 1983; Tannock et al., 1988), yet, the
recognition of psychological distress is handicapped by
patients' unwillingness to disclose any emotional problems
and doctors' and nurses' reluctance to enquire (Maguire et
al., 1980). Ways of improving the identification of psycho-
logical morbidity need to be found and a self-assessment
approach warrants evaluation. Two self-report question-
naires, The Hospital Anxiety and Depression Scale (HADS)
(Zigmond & Snaith, 1983) and The Rotterdam Symptom
Checklist (RSCL) (de Haes et al., 1990), seemed promising
since they were both designed for use with physically ill
patients. However, there is little published data concerning
their performance in homogeneous cancer groups.
A study was conducted to determine how well these two
questionnaires identified depressive illness and anxiety states
in patients with advanced cancer of the breast.
Patients and methods
Patients with advanced cancer of the breast attending
medical oncology outpatient clinics over a 12 month period
were included, providing they were free from dementia or
cerebral metastases.
A research nurse explained the study and asked each
patient to complete the two questionnaires. The HADS is
designed to discriminate between anxiety and depression and
is made up of a 7-item anxiety subscale and a 7-item depres-
sion subscale. Each item (for example, 'I can laugh and see
the funny side of things') is rated on a 4-point scale (e.g. as
much as-I always do (0); not quite so much (1); definitely not
so much (2); and not at all (3), giving maximum subscale
scores of 21 for depression and anxiety respectively. The
questionnaire assessed symptoms over the preceding week.
The authors of the HADS suggested that scores > 11 on
either subscale were indicative of a case of depression or a
case of clinical anxiety, whilst subscale scores in the 8-10
range represented borderline cases.
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The RSCL contains three subscales: physical symptomato-
logy due to disease and/or treatment (22 items); psycho-
logical symptoms (8 items) and activities of daily living (8
items). All items are rated on a 4-point scale (e.g. 'I feel
tense'; not at all (0); a little (1); somewhat (2); very much
(3)). The psychological subscale yields a maximum score of
24. The questionnaire assessed symptoms over the preceding
3 days.
The order in which these questionnaires were completed by
patients was balanced so that they were equally represented
in first and second positions. Their presentation was
therefore alternated as each consecutive clinical session in
which patients were being recruited.
Consecutive patients with a high score on either question-
naire were asked ifthey were willing to be interviewed for the
research by the psychiatrist. With respect to the HADS, 'high
scorers' were those patients with scores at or above the
recommended threshold value of 11, on either subscale. The
same value for the psychological subscale of the RSCL was
selected following discussion with one of its authors (Pruyn,
personal communication, 1983). In addition to patients with
a high score, some patients with a low questionnaire score
were also approached. This normally involved asking the
next low scoring patient following a high scorer. Thirty-four
patients had high scores on the HADS and 47 patients had
low scores. Using the RSCL, 27 patients had scores > 11 on
the psychological complaints subscale and 54 had low scored
(i.e. < 10). In total 44 patients out of the 81 recruited had a
high score on either the HADS (17) or the RSCL (10) or
both (17). Thirty-seven patients had low scores on both
questionnaires. The interviews were conducted by a clinical
psychiatrist (PH), who was blind to the questionnaire scores,
using the Clinical Interview Schedule (Goldberg et al., 1970)
with additional questions in order to apply standardised
psychiatric diagnostic criteria (DSM III) (American Psychiat-
ric Association, 1980).
A diagnosis of depressive illness required the presence of
depressed mood for a minimum of 4 weeks, plus at least four
of the following symptoms: change in appetite or weight;
insomnia or hypersomnia; psychomotor agitation or retarda-
tion; loss of interest including loss of libido; worthlessness or
guilt; diminished concentration or suidical ideas. The diag-
nosis of an anxiety state required the presence of generalised
persistent anxiety of at least one month's duration, together
with symptoms from three of four categories: motor tension
(for example, shakiness, tension, fidgeting); autonomic hyper-
activity (for example, dizziness, paraesthesia, diarrhoea);
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apprehensive expectation (for example, worry, fear, anxious
foreboding); and vigilance and scanning (for example, dist-
ractibility, poor concentration and irritability).
Where physical symptoms were clearly attributable to
disease or treatment (for example, fatigue) they were ignored.
Patients found to have symptoms of depression or anxiety,
but insufficient to meet these DSM III criteria were desig-
nated 'borderline' cases.
Results
Two hundred and four patients completed the two question-
naires and 18 patients refused, giving a compliance rate of
92%. Eight-one patients agreed to be interviewed and there
were no refusals.
Treatment
Of the 81 patients interviewed 37 were receiving endocrine
therapy, 24 were receiving chemotherapy, seven were taking
corticosteroids and 13 were not receiving treatment.
Psychiatric morbidity
Twenty (25%) patients were found at interview to have a
depressive illness and/or anxiety state while 11 (14%) patients
had a borderline mood disorder.
Performance ofthe two questionnaires in the study sample
The sensitivity and specificity were calculated for the HADS
anxiety and depression subscales and the RSCL psycho-
logical complaints subscale, using both the recommended
threshold score (11) and a range of alternative cut-off scores.
Sensitivity indicated the proportion of correctly identified
cases (number of true cases/number of true cases plus
number of false negatives) and hence the rate of false nega-
tives. Specificity indicates the proportion of correctly identi-
fied non-cases (number of true non-cases/number of true
non-cases plus number of false positives) and hence the false
positive rate (1-specificity). The misclassification rate is cal-
culated from the ratio false positives + false negatives/total
number of sample.
Table I shows the performance of the two questionnaires
based on the sample interviewed. Optimum sensitivity and
specificity was found with a cut off value of 11 for each scale.
The raw data used to calculate these values are shown in
Table II. The sensitivity and specificity of each questionnaire
were comparable and in an acceptable range. The misclass-
ification rate for the HADS anxiety subscale (12%), was
considerably lower than that for the depression subscale
(25%).
An analysis was also carried out on the HADS using
combined subscale scores to compare its performance as a
unitary 14 item scale. The best cut-off score was 18, for
which the sensitivity was 75%, specificity 74% and misclass-
ification rate 26% (see Table III).
Performance ofthe two questionnaires in true community
conditions
Sensitivity and specificity are dependent on the ratio of high
and low scores in the sample. We deliberatedly balanced this
ratio in approximately equal proportions for the interview
study, in order to include as many potential 'cases' as possi-
ble for the validation exercise. The outpatient population,
from which the study sample was drawn, included more low
scorers (133, 65%) than the interviewed sample (46%). Simi-
larly the prevalence ofhigh scorers was lower in the complete
sample (71, 35%) than in the interviewed group (54%). It
was desirable, therefore, to re-calculate the proportion of
'cases' to 'non-cases' in the interviewed sample to reflect the
prevalence of high scorers and low scorers in the 204 out-
patient attenders who completed both questionnaires.
Sensitivity and specificity values were then recalculated
using these 'weighted' values for cases and non-cases, the
results are shown in Table IV. The combined HADS sub-
scales were used for this part of the analysis. Whilst the
specificity remained relatively unchanged, the sensitivity of
the HADS improved from 75% to 81% and that of the
RSCL fell from 75% to 71%. The prevalence of probable
cases in the whole sample (204) was calculated using the
formula
'weighted' no. cases x 100
total no. patients screened
34.71 x 100
204
The estimated prevalence for the whole sample screened was
17%.
Predictive values
The accuracy of a screening instrument is also dependent on
its positive predictive value (PPV) (Vecchio, 1966), that is the
Table I Sensitivity, specificity andmisclassification rate for the RSCL
psychological complaints subscale, HADS anxiety and depression
subscales, based on the interviewed sample
HADS HADS
RSCL anxiety depression
Sensitivity % 75 75 75
Specificity % 80 90 75
Misclassification rate % 21 12.3 24.7
Table II Ratio ofcases tonon-cases, identifiedbyclinicalinterview, at
the optimum threshold value for each questionnaire
Psychiatric assessment
Non-cases Cases
(i) HADS depression
Scores
0-10 49 4
11 + 16 12
(ii) HADS anxiety
Scores
0-10 62 3
11 + 7 9
(iii) RSCL Psychological complaints
Scores
0-10 49 5
11 + 12 15
TableIII Ratioofcasestonon-casesasidentifiedbyclinicalinterview,
using a cut-off score of 18 for the HADS questionnaire (anxiety and
depression scores combined)
Psychiatric assessment
Non-cases Cases
Scores
0-17 45 5
18 + 16 15
Sensitivity = 75%; Specificity = 74%.
Table IV 'Weighted' data used to calculate the sensitivity and
specificity of the HADS and RSCL questionnaires in true outpatient
conditions
Psychiatric assessment
Non-cases Cases
(i) HADS
Low scorers 140.30 6.70
High scorers 28.98 28.01
Sensitivity 80.7%; Specificity 88.88%.
(ii) RSCL
Low scorers 150.06 9.22
High scorers 19.22 24.77
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probability of a high score being a true psychiatric case. In
clinical practice this value is important in determining the
utility of an instrument, since it indicates the probability of
detecting cases in a given population of patients. It is cal-
culated from the ratio of the number of correctly identified
cases/total number ofpersons with high scores. The PPV of a
screening test is dependent on a prevalence in a given popula-
tion and increases as prevalence rises. The PPV for the RSCL
was 55.6%, which is high. For the HADS scale overall the
value was 49.6% which is also very acceptable; the PPV for
the anxiety subscale was 56.3% and that for the depression
subscale 42.9%. (Using weighted data, the values for the two
questionnaires were 56.3% and 49.2% respectively.) The neg-
ative predictive values (NPV) were also calculated, that is,
the proportion of low scorers who are not cases. The value
for the RSCL was 80.3% and that for the HADS 82.7%. In
other words, both questionnaires used as screening instru-
ments would correctly identify one in every two high scorers
as a case and have a relatively low risk of misclassifying a
low scorer as a case. The ability of the HADS to accurately
detect anxiety cases is high but its performance to detect case
depression more modest.
Borderline affective disorder
The HADS questionnaire has been used to discriminate
patients with borderline depression and anxiety using scores
in the 8-10 range (Zigmond & Snaith, 1983). Of the patients
interviewed, three out of six patients with a diagnosis of
borderline anxiety and three out of eight with borderline
depression were misclassified as cases by the HADS using the
range of scores suggested by Zigmond and Snaith. Further
analysis of the HADS in the borderline range of scores is
underway but will not be reported here.
Discussion
The statistical analyses indicated that both questionnaires
performed reasonably well and were suitable for use as
screening instruments. However, both warrant refinement to
improve their accuracy in detecting cases. Using the HADs
as a 14-item scale, our results are very similar to those
reported by Razavi et al. (1990), who suggested an optimal
cut off point of 19 for major depressive disorder, associated
with 70% sensitivity and 25% false positive rate. (Our cut off
point of 19 gave exactly the same sensitivity and specificity
values, but a threshold of 18 was superior from our data.)
When using the separate subscales, the performance of the
anxiety subscale was superior to that for depression, in terms
of its positive predictive power and false positive rate. Our
cut off value of 11 with the HADS depression subscale is a
little higher than that reported by Razavi, but a lower value
gave an unacceptable false positive rate (39%) with our data.
When screening for illness, it is desirable to achieve a
100% detection rate. Whilst this can be achieved with these
questionnaires, it is only at the expense of including a high
proportion of false positives, which would create an unac-
ceptable interview load.
In clinical practice, patients with high scores warrant fur-
ther assessment by a brief interview, as it is posisble to
discriminate true cases from false positives on this basis. The
'optimal' sensitivity is aimed to identify an acceptable
balance in terms of accuracy and clinical feasibility. An
instrument with good predictive power is very valuable, since
it will reduce the interview load. The RSCL was superior to
the HADS in this respect.
Patients misclassified by both questionnaires are worth
examining in greater detail. Of the five cases who were false
negatives according to the RSCL, four were identified by the
HADS, completed on the same occasion. Similarly, the
RSCL identified two cases missed by the HADS, suggesting
that the use of two questionnaires concurrently or sequen-
tially may be of benefit. Other factors may have contributed
to the misclassification rate: firstly the clinical 'case' defin-
ition may have been too stringent, and hence the cut off
score set too high. Secondly, the omission of somatic items
that were thought due to disease or treatment may have
raised the threshold for the clinical diagnosis. Further work
in much larger samples is currently underway to assess the
importance of somatic items in the diagnosis of psychiatric
morbidity in cancer patients. A current advantage in both
questionnaires tested in this study is that they exclude som-
atic items from the psychological subscales.
Among the false positive scores were two patients with
anxious personalities and two with bereavement reactions,
and the questionnaires were not expected to discriminate
such cases. Also included were patients with borderline
depression or anxiety as judged by a clinical interview. Some
of these patients would fulfill a DSM diagnosis ofadjustment
disorder (not used in this analysis). Such reactions may give
rise to substantial psychological distress but this does not
necessarily correlate with a formal psychiatric diagnosis of
depressive illness or anxiety state.
The estimated prevalence of psychological illness, from the
'weighted' data, may be considered low at 17% and ideally
the prevalence should be derived from an independent sample
from the same population. However, this prevalence is
double the psychological morbidity reported by Dean (1987)
in a sample of patients with early breast cancer. Like Dean,
standard methods for defining psychiatric illness were used in
this study, and strict criteria for defining a case were applied.
Derogatis et al. (1983) reported a prevalence rate for psycho-
logical morbidity of 47% in a heterogenous sample of cancer
patients, but of these only 13% were ascribed as DSM III
diagnosis of depressive disorder or anxiety state. Sixty-eight
per cent of their diagnoses were deemed to be adjustment
reactions.
It proved feasible to use both questionnaires in a busy
clinical setting. The HADS has the advantage of being short,
and of discriminating to an extent between cases of depres-
sion and anxiety. The RSCL has additional useful questions
about other aspects of the patients' quality of life, namely
physical symptoms, treatment toxicity and functional status.
Other instruments have been produced specifically for use in
cancer research or practice (Bell et al., 1985; Coates et al.,
1987; Padilla et al., 1981; Priestman & Baum, 1976; Selby et
al., 1984) but these have not been validated against a psych-
iatric interview. This makes their scores difficult to interpret.
The performance of these questionnaires is much superior
to the detection rate of doctors and nurses involved in cancer
care. Only 22% of patients with psychological problems
following mastectomy are recognised by those concerned
with their aftercare (Maguire et al., 1980). However, Maguire
found that specialist nurses trained to detect such problems,
can identify up to 80% of patients with depression or an
anxiety state. A two stage process of assessment could be
used, in which patients are serially screened for psychiatric
disorder using one of these questionnaires. Those with above
threshold scores would then be assessed further by a
specialist nurse. This would provide a practical way of iden-
tifying patients who might need help in the setting of a busy
oncology clinic. Such screening questionnaires could also be
used in clinical trials to measure the psychological dimension
of quality of life.
In using either questionnaire as a screening instrument
careful preparation is advisable: sensitivity, specificity and
cut-off values should be checked, and the predictive value
should be calculated according to the known prevalence of
affective disorder in the population of patients to be screen-
ed. Used in this way, these two instruments will provide a
valuable clinical tool in the detection of psychological mor-
bidity.
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